Sign in
CompletedNo phase

Prediction of Reverse Remodeling and Outcome in Patients With Severe Secondary Mitral Valve Regurgitation Undergoing Transcatheter Edge-to-edge Mitral Valve Repair

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
39 people enrolled
Started
4 Aug 2021
Ended
30 Sept 2026
Type of study
Interventional
Treatments tested
  • Cardiac magnetic resonance imaging before the procedure
  • Transcatheter mitral edge-to-edge repair.
Record updated
6 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients with severe secondary MR characterized, according to the European guidelines and recommendations, by a regurgitant volume ≥30 mL/beat or an effective regurgitant orifice ≥20 mm²
  • Symptomatic patients with New York Heart Association Class ≥II
  • Left ventricular ejection fraction between 15% and 50%
  • Optimal standard of care therapy for heart failure according to investigator
  • Not eligible for a mitral surgery intervention according to the Heart Team
  • Patients who have the ability to understand the requirements of the study and provide written consent/assent to participate and agree to abide by the study requirements

Who cannot take part

  • Patients with untreated severe concomitant valve disease (e.g. severe tricuspid valve regurgitation, aortic stenosis)
  • The patient has a medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up
  • The patient has contraindications to CMR, including: Implanted non-CMR conditional metallic implants, pacemaker, intracardiac defibrillator, neurostimulator, epicardial pacemaker leads, or any abandoned leads, ferromagnetic aneurysm clip, ferromagnetic halo device, cochlear implants, implanted infusion pumps or severe claustrophobia
  • The patient is clinically unstable or has stage D congestive heart failure or inability to lay flat for 60 minutes
  • Severe impaired renal function (GFR < 15 ml/min)
  • Participants younger than 18 years
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigators' hypothesis is that CMR tissue characterization and myocardial function analysis acquired by CMR feature tracking technique predict reverse remodeling in patients with severe secondary mitral regurgitation (MR) undergoing transcatheter mitral edge-to-edge repair.

The group in the trial

  • Treatment ArmTreatment being tested

    Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.

    Treatment: Cardiac magnetic resonance imaging before the procedure and Transcatheter mitral edge-to-edge repair.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 November 2026